Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 3/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23099950 | 0.85 | RUNX1 (0.42) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL12422184 | 0.82 | CA12 (0.61) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL24313612 | 0.81 | L3MBTL1 (0.47) | GPR3GRM7HCRTR1HCRTR2 | |
| SCHEMBL30776243 | 0.80 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL481218 | 0.80 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8302095 | 0.79 | GPR3 (0.44) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL5158453 | 0.79 | ALDH1A1 (0.46) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL17484615 | 0.78 | PPARA (0.42) | GPR3GRM7 | |
| SCHEMBL22714098 | 0.78 | GPR3 (0.48) | GPR3SCN5A | |
| SCHEMBL6568256 | 0.78 | GPR3 (0.42) | GPR3CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551846-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031191-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AS RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6479486-B2 | ANTIDEPRESSANTS, ANALGESICS | MERCK SHARP & DOHME LTD. (GB) | 2002-11-12 | — | — | US | disclosed |
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147207-A1 | AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | GLRA1, GLRA2, CCKBR | GPR3 242/4885CA12 1013/4885CA1 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.